These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1959450)

  • 1. Tritylase antibodies.
    Iverson BL; Iverson SA; Cameron KE; Jahangiri GK; Pasternak DS; Lerner RA
    Ciba Found Symp; 1991; 159():227-33; discussion 234-5. PubMed ID: 1959450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The generation of antibody combining sites containing catalytic residues.
    Shokat KM; Schultz PG
    Ciba Found Symp; 1991; 159():118-28; discussion 128-34. PubMed ID: 1959444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyclonal antibody catalytic variability.
    Stephens DB; Thomas RE; Stanton JF; Iverson BL
    Biochem J; 1998 May; 332 ( Pt 1)(Pt 1):127-34. PubMed ID: 9576860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catalytic polyclonal antibodies.
    Stephens DB; Iverson BL
    Biochem Biophys Res Commun; 1993 May; 192(3):1439-44. PubMed ID: 8507208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that the mechanism of antibody-catalysed hydrolysis of arylcarbamates can be determined by the structure of the immunogen used to elicit the catalytic antibody.
    Boucher G; Said B; Ostler EL; Resmini M; Brocklehurst K; Gallacher G
    Biochem J; 2007 Feb; 401(3):721-6. PubMed ID: 17020536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-directed mutagenesis provides insights into the selective binding of trityl derivatives to Plasmodium falciparum dUTPase.
    Recio E; Musso-Buendía A; Vidal AE; Ruda GF; Kasinathan G; Nguyen C; Ruiz-Pérez LM; Gilbert IH; González-Pacanowska D
    Eur J Med Chem; 2011 Aug; 46(8):3309-14. PubMed ID: 21600680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esterolytic antibodies as mechanistic and structural models of hydrolases-a quantitative analysis.
    Lindner AB; Kim SH; Schindler DG; Eshhar Z; Tawfik DS
    J Mol Biol; 2002 Jul; 320(3):559-72. PubMed ID: 12096909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the mechanism of action of a catalytic antibody.
    Martin MT; Schantz AR; Schultz PG; Rees AR
    Ciba Found Symp; 1991; 159():188-97; discussion 197-200. PubMed ID: 1959447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bait and switch hapten strategy generates catalytic antibodies for phosphodiester hydrolysis.
    Wentworth P; Liu Y; Wentworth AD; Fan P; Foley MJ; Janda KD
    Proc Natl Acad Sci U S A; 1998 May; 95(11):5971-5. PubMed ID: 9600901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A polyclonal antibody preparation with Michaelian catalytic properties.
    Gallacher G; Jackson CS; Searcey M; Badman GT; Goel R; Topham CM; Mellor GW; Brocklehurst K
    Biochem J; 1991 Nov; 279 ( Pt 3)(Pt 3):871-81. PubMed ID: 1953683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new strategy for the generation of catalytic antibodies.
    Shokat KM; Leumann CJ; Sugasawara R; Schultz PG
    Nature; 1989 Mar; 338(6212):269-71. PubMed ID: 2922053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological optimization of a generic hydrophobic pocket for high affinity hapten binding and Diels-Alder activity.
    Piatesi A; Hilvert D
    Chembiochem; 2004 Apr; 5(4):460-6. PubMed ID: 15185369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Peculiarities of the Mechanism of Interactions of Catalytic Antibodies with Organophosphorus Substrates].
    Mokrushina YA; Pipiya SO; Stepanova AV; Shamborant OG; Knorre VD; Smirnov IV; Gabibov AG; Vorobiev II
    Mol Biol (Mosk); 2017; 51(6):958-968. PubMed ID: 29271960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding and multiple hydrolytic sites in epitopes recognized by catalytic anti-peptide antibodies.
    Paul S; Johnson DR; Massey R
    Ciba Found Symp; 1991; 159():156-67; discussion 167-73. PubMed ID: 1720373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catalytic antibody model and mutagenesis implicate arginine in transition-state stabilization.
    Roberts VA; Stewart J; Benkovic SJ; Getzoff ED
    J Mol Biol; 1994 Jan; 235(3):1098-116. PubMed ID: 8289310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis for antibody catalysis of a cationic cyclization reaction.
    Zhu X; Heine A; Monnat F; Houk KN; Janda KD; Wilson IA
    J Mol Biol; 2003 May; 329(1):69-83. PubMed ID: 12742019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large rate accelerations in antibody catalysis by strategic use of haptenic charge.
    Thorn SN; Daniels RG; Auditor MT; Hilvert D
    Nature; 1995 Jan; 373(6511):228-30. PubMed ID: 7816136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New strategies for the design of catalytic antibodies.
    Janda KD
    Biotechnol Prog; 1990; 6(3):178-81. PubMed ID: 1366610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition-state stabilization as a measure of the efficiency of antibody catalysis.
    Stewart JD; Benkovic SJ
    Nature; 1995 Jun; 375(6530):388-91. PubMed ID: 7760931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the hydrolytic activity of a polyclonal catalytic antibody preparation by pH-dependence and chemical modification studies: evidence for the involvement of Tyr and Arg side chains as hydrogen-bond donors.
    Resmini M; Vigna R; Simms C; Barber NJ; Hagi-Pavli EP; Watts AB; Verma C; Gallacher G; Brocklehurst K
    Biochem J; 1997 Aug; 326 ( Pt 1)(Pt 1):279-87. PubMed ID: 9337880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.